Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dextroamphetamine sulfate
Drug ID BADD_D00637
Description Dextroamphetamine is the dextrorotary enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label].
Indications and Usage Used to treat attention deficit hyperactivity disorder (ADHD).
Marketing Status Prescription; Discontinued
ATC Code N06BA02
DrugBank ID DB01576
KEGG ID D02078
MeSH ID D003913
PubChem ID 5825
TTD Drug ID D0T3LF
NDC Product Code 24338-855; 0406-8958; 63629-2374; 24338-856; 75826-125; 0115-9927; 11534-188; 24338-852; 64896-674; 13107-036; 13107-035; 0406-8961; 45963-304; 43386-870; 43386-871; 51862-346; 0555-0952; 24338-853; 10702-065; 75826-121; 75826-120; 52536-510; 0115-9928; 52536-500; 24338-850; 51634-0222; 0115-9929; 11014-0322; 68382-944; 75826-126; 61960-0210; 51862-345; 11014-0323; 45963-303; 0406-8960; 51862-344; 0555-0953; 0406-8962; 52536-520; 64896-675; 68382-941; 0406-8959; 52536-530; 68382-942; 75826-124; 24338-851; 68382-943; 11534-189; 68382-945; 11014-0324; 45963-305; 10702-066; 66993-359; 49812-0058; 24338-854; 63629-2375; 21724-701; 75826-123; 75826-122; 0406-1950; 64896-673; 52536-515; 65392-0114
Synonyms Dextroamphetamine | Dexamphetamine | Dexamfetamine | dextro-Amphetamine | dextro Amphetamine | d-Amphetamine | d Amphetamine | Dexedrine | DextroStat | Oxydess | Curban | Dextroamphetamine Sulfate | Sulfate, Dextroamphetamine | Dextro-Amphetamine Sulfate | Dextro Amphetamine Sulfate | d-Amphetamine Sulfate | d Amphetamine Sulfate
Chemical Information
Molecular Formula C18H28N2O4S
CAS Registry Number 51-63-8
SMILES CC(CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N.OS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug dependence19.07.02.009--Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.004--Not Available
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dysphoria19.04.02.004--Not Available
Euphoric mood19.04.02.006--
Extrasystoles02.03.02.003--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flushing23.06.05.003; 24.03.01.002; 08.01.03.025--
Gastrointestinal disorder07.11.01.001--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Hallucination19.10.02.002--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hyperpyrexia08.05.02.002--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypersomnia19.02.05.001; 17.15.01.001--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Irritability19.04.02.013; 08.01.03.011--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Loss of consciousness17.02.04.004--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages